[ TRANSACTION RECORD ]

Eli Lilly and Company Investment in DICE Therapeutics — 2023

VERIFIED VECTOR ID: 001901 · tx-097-2
M SOURCE NODE — FUNDER
Eli Lilly and Company
Healthcare United States
$2,400,000,000
EQUITY
09/08/2023
Q DESTINATION NODE — RECIPIENT
DICE Therapeutics
Company United States
Amount (USD)
$2.4B
Flow Type
EQUITY
Transaction Date
09/08/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Eli Lilly and Company
AUM 640000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity DICE Therapeutics
Entity Type Company
Jurisdiction United States
Intelligence Note

Eli Lilly and Company completed the acquisition of DICE Therapeutics for approximately 2.4 billion dollars to expand its portfolio in chronic immunology. The transaction centers on DICE’s oral small molecule platform for treating autoimmune disorders. This deal illustrates Lilly’s strategy of acquiring innovative biotech firms to replace injectable biologic therapies.

Σ
Primary Forensic Source https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-dice-therapeutics/
✓ SOURCE LINKED